Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.34 |
| ▸ | MMP9 | P14780 | 4/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP12 | P39900 | 3/20 | 0.34 |
| ▸ | MMP14 | P50281 | 3/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14241031 | 1.00 | GLP1R (0.48) | GLP1RMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL21440821 | 1.00 | GLP1R (0.48) | GLP1RMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL21440827 | 0.97 | GLP1R (0.50) | GLP1RMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL71086 | 0.97 | GLP1R (0.50) | GLP1RMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL14240744 | 0.97 | GLP1R (0.50) | GLP1RMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL21440837 | 0.95 | GLP1R (0.55) | GLP1RFOLH1 | |
| SCHEMBL25662188 | 0.95 | GLP1R (0.55) | GLP1RFOLH1 | |
| SCHEMBL23874254 | 0.93 | GLP1R (0.56) | GLP1RFOLH1 | |
| SCHEMBL24253205 | 0.93 | GLP1R (0.54) | GLP1RMMP2MMP9MMP8MMP12 | |
| SCHEMBL25662184 | 0.93 | GLP1R (0.56) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330189-A1 | ACYLATED GLP-1 DERIVATIVE | Sciwind Biosciences Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-8835379-B2 | Derivatives of CGRP | NOVO NORDISK A/S (DK) | 2014-09-16 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20100029903-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | GLP1R 1/4885MEN1 357/4885KMT2A 4148/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885MEN1 922/4885KMT2A 2972/4885 |
| US-20100029903-A1 | Polypeptide Protracting Tags | LAS1L, SEC16A, PHAX | GLP1R 37/4885MEN1 2188/4885KMT2A 3483/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | GLP1R 1/4885MEN1 2539/4885KMT2A 2739/4885 |
| US-20230330189-A1 | ACYLATED GLP-1 DERIVATIVE | GLP1R, GIPR, IAPP | GLP1R 1/4885MEN1 388/4885KMT2A 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.